The global injectable thyroid drug market is set to surge at a CAGR of 5.7% by 2034. The industry is projected to increase from US$ 439.65 million in 2024 to US$ 765.4 million by 2034. In 2023, the market was valued at US$ 414.4 million.
| Attributes | Details |
|---|---|
| Base Value, 2023 | US$ 414.4 million |
| Injectable Thyroid Drug Market Size, 2024 | US$ 439.65 million |
| Projected Revenue, 2034 | US$ 765.4 million |
| Value-based CAGR (2024 to 2034) | 5.7% |
Rising prevalence of thyroid disorders is a significant health concern affecting a large number of individuals globally. Thyroid disorders, including conditions such as hypothyroidism, hyperthyroidism, and thyroid nodules, have been on the rise in recent years, fueling growth.
Factors such as genetic predisposition, environmental influences, and lifestyle changes are propelling demand for injectable thyroid drugs.
As the global population continues to be affected by thyroid conditions such as hypothyroidism and hyperthyroidism, demand for effective treatments, including injectable medications, is gaining traction.
Women, individuals over the age of 60, and those with a family history of thyroid problems are at a high risk of developing thyroid disorders. Furthermore, factors such as iodine deficiency, autoimmune diseases, and exposure to radiation are set to increase the likelihood of thyroid dysfunction.
Thyroid conditions affect over 12% of the United States population at some point in their lives, with an estimated 20 million having thyroid diseases. Rising shift toward personalized medicine offers potential for developing personalized therapies based on an individual's genetic profile, potentially enhancing treatment outcomes.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The industry recorded a historical CAGR of 5% from 2019 to 2023. Increasing incidence of chronic diseases such as diabetes, cancer, and autoimmune disorders led to a high demand for injectable medicines. These conditions often require long-term or lifelong treatment, creating a sustained market worldwide.
Developments in drug delivery systems and formulations have broadened the range of conditions treatable with injectable medicines. It is projected to lead to the development of innovative treatments for various diseases. Injectable medications offer benefits such as improved bioavailability, precise dosing, and reduced dosing frequency compared to oral medications.
By 2034, the industry is set to surge at 5.7% CAGR. Growing preference for injectable treatments and improved medication adherence are fueling growth in the injectable medicine market. This trend is particularly relevant for autoimmune diseases, particularly thyroid-related ones.
Novel injectable thyroid medications are set to improve patient outcomes by addressing specific needs, such as precise dosing and enhanced therapeutic efficacy. Rising adoption of injectable drugs has positively impacted the industry by surging innovation and addressing therapeutic needs in the management of thyroid disorders.
Growing awareness of thyroid treatment is projected to increase screenings and diagnoses of thyroid disorders. It is anticipated to create a large patient pool for pharmaceutical companies producing thyroid drugs. This growth presents an opportunity for companies to invest in research & development to develop novel, more effective thyroid drugs that cater to the evolving needs of patients.
Rising awareness of thyroid diagnosis is set to lead to collaborations between pharmaceutical companies, healthcare providers, and patient advocacy groups to develop educational materials and resources.
Growing focus on thyroid diagnosis is further set to encourage regulatory support for innovative treatments. It is set to allow pharmaceutical companies to address unmet medical needs and improve patient education & adherence.
Principal Consultant
Injectable medications have more complex manufacturing processes than oral formulations, leading to high production costs for formulation development, quality control, and packaging. The administration of injectable drugs often needs healthcare professionals. It also requires training, expertise, and time, which increases the cost of the treatment and hinders growth.
The table below showcases revenues in terms of the top five leading countries spearheaded by Canada and France. The countries are projected to lead the industry through 2034.
In North America, Canada is set to lead the industry at a CAGR of 5.6% by 2034. This growth is attributed to increasing demand for more effective and targeted thyroid treatments. In Europe, the United Kingdom is anticipated to showcase a CAGR of 3.0% by 2034.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| United States | 4.2% |
| Germany | 3.8% |
| Canada | 5.6% |
| United Kingdom | 3.0% |
| France | 5.3% |
The United States is projected to exhibit a CAGR of 4.2% throughout the forecast period. The country has a substantial population. Thyroid disorders are relatively common, which is leading to a high demand for thyroid medications across the country.
The United States has a sophisticated healthcare system with unique facilities, specialized professionals, and diagnostic capabilities. These are enabling the diagnosis and treatment of thyroid disorders.
The regulatory framework in the United States, particularly overseen by the Food and Drug Administration (FDA), ensures high standards of safety, efficacy, and quality for thyroid medications. This instills confidence in both domestic and international markets, further consolidating the country’s position in the global injectable thyroid drug industry.
By 2034, Germany is set to lead the industry in Europe. It is projected to rise at a CAGR of 3.8% by 2034.
Germany places a strong emphasis on research and development, propelling innovation in the pharmaceutical and healthcare sectors. This commitment to advancing medical knowledge and producing high-quality thyroid drugs has led to the country’s prominent presence in the global industry.
Germany upholds stringent regulatory standards for pharmaceuticals through institutions such as the Federal Institute for Drugs and Medical Devices. These regulatory standards ensure the quality, safety, and efficacy of thyroid medications, propelling demand in the industry.
China occupied a substantial value share in the global market in 2023 and is projected to rise at a CAGR of 7.7% during the forecasted period. The country has seen a rise in the prevalence of thyroid disorders.
It is attributed to factors such as changing lifestyles, dietary patterns, and environmental influences. This surge in thyroid conditions has created a high demand for effective treatments, including injectable medications.
China's healthcare infrastructure is growing rapidly, leading to improved diagnosis, treatment, and management of various medical conditions, including thyroid disorders. Rising focus on healthcare facilities and services are the key factors propelling growth in the country.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The section below throws some light on leading revenue-generation segments and their future growth rates. Leading companies can utilize this data to invest in demanding products and services to boost their sales and stay ahead of the competition.
| Molecules | Value CAGR (2024 to 2034) |
|---|---|
| Levothyroxine Sodium | 5.1% |
| Liothyronine Sodium | 5.4% |
Levothyroxine sodium is leading the molecule segment and is majorly used in the treatment of hypothyroidism. It is the most prescribed thyroid medication due to its effectiveness in supplementing the deficient thyroid hormone levels in the body.
This medication is available in multiple dosage forms, including tablets and injectable formulations. Hence, it provides flexibility in treatment options for patients with thyroid disorders.
By 2034, the liothyronine sodium segment is set to rise at a CAGR of 5.4%. Injectable liothyronine sodium is commonly used in hospitals and emergency settings for precise dosing and monitoring under medical supervision.
It is set to be a part of a comprehensive treatment regimen for ill patients with severe hypothyroidism. Its use is also projected to rise in customized treatment regimens involving combination therapy or patient-specific adjustments.
| Sales Channel | Value CAGR (2024 to 2034) |
|---|---|
| Hospitals | 5.1% |
| Specialty Clinics | 5.2% |
| Retail Pharmacies | 5.5% |
Hospitals accounted for 33.5% industry share and are set to rise at a CAGR of 5.1% over the forecasted period. Hospitals serve as primary healthcare institutions catering to a diverse patient population, including individuals with varying degrees of thyroid disorders.
This wide patient reach creates a substantial market for injectable thyroid drugs. Hospitals are often the first point of contact for diagnosis, treatment, and management of thyroid conditions.
By 2034, the retail pharmacies segment is set to lead the sales channel category. Retail pharmacies provide injectable thyroid drugs to patients stocked with various formulations and brands.
Pharmacists educate patients on proper & accurate administration techniques, dosage instructions, side effects, and medication adherence. They offer medication management services such as synchronization, refill reminders, and therapy management to optimize treatment outcomes and improve patient adherence.
Leading producers and companies are strategically focusing on collaborations, mergers, distribution agreements, acquisitions, and partnerships to stay competitive.
This reflects an industry commitment to innovation and a way to address evolving demands. New product launches and developments are a powerful promotional strategy for companies, showcasing their commitment to innovation and scientific development.
The industry includes three key molecules, namely, levothyroxine sodium, liothyronine sodium, and recombinant human TSH.
The three key indications are hypothyroidism, hyperthyroidism, and thyroid cancer.
Leading sales channels in the industry include hospitals, specialty clinics, retail pharmacies, and mail-order pharmacies.
Key countries of North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe, and Middle East and Africa are covered.
The industry was valued at US$ 414.4 million in 2023.
The industry is set to reach US$ 439.65 million in 2024.
Demand for injectable thyroid drugs is slated to rise at a 5.7% CAGR by 2034.
The industry is set to reach US$ 765.4 million in 2034.
Genzyme Corporation (Sanofi), Fresenius Kabi, and XGEN PHARMACEUTICALS DJB, Inc.
Hypothyroidism segment is estimated to lead in 2024.
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034 5.1. By Molecule 5.2. By Indication 5.3. By Sales Channel 5.4. By Region 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Molecule 6.1. Levothyroxine Sodium 6.2. Liothyronine Sodium 6.3. Recombinant Human TSH 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Indication 7.1. Hypothyroidism 7.2. Hyperthyroidism 7.3. Thyroid Cancer 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Sales Channel 8.1. Hospitals 8.2. Specialty Clinics 8.3. Retail Pharmacies 8.4. Mail Oder Pharmacies 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region 9.1. North America 9.2. Latin America 9.3. Western Europe 9.4. Eastern Europe 9.5. East Asia 9.6. South Asia and Pacific 9.7. Middle East and Africa 10. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 11. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 12. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 13. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 14. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 15. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 16. Middle East and Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 17. Sales Forecast 2024 to 2034 by Molecule, Indication, and Sales Channel for 30 Countries 18. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 19. Company Profile 19.1. Genzyme Corporation (Sanofi) 19.2. Fresenius Kabi 19.3. XGEN PHARMACEUTICALS DJB, Inc. 19.4. Zydus Lifesciences 19.5. DMS Pharma 19.6. MAIA Pharmaceuticals, Inc. 19.7. App Pharmaceuticals
Explore Healthcare Insights
View Reports
Injectable Thyroid Drug Market
